Navigation Links
Schering-Plough Announces Presentation of Phase II Trial Results,for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual,Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

The Phase II trial, with an abstract titled Results of a Multinational, Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, will be presented by the TRA-PCI investigators.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.sch ering-plough.com.

CONTACT: Media Contact: Lee A. Davies, +1-908-298-7127; or InvestorContact: Alex Kelly, +1-908-298-7436

Web site: http://www.schering-plough.com/

Ticker Symbol: (:SGP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Cardiology devices segment is anticipated to ... The Cardiology Devices segment is likely to create absolute ... in 2018 over 2017. By the end of 2027, Cardiology ... to US$ 700 Mn, expanding at a CAGR of 18.4% ... Asia Pacific reprocessed medical devices market ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... Michael Vick announced ... transforming the quarterback position. The former overall number one pick in the 2001 NFL ... career. He holds the record for the most career rushing yards by a quarterback ...
(Date:4/24/2017)... ... 2017 , ... As part of the nationwide Days of Remembrance effort led ... Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced ... trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection of ... is proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder ... of the Board and launched a national search to find a visionary new leader to ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking into ... depicts every parent’s worst nightmare, when her three children were violently taken from her. ... my divorce,” James said. “After the death of my children, I continued to journal. ...
(Date:4/24/2017)... ... April 24, 2017 , ... The ... public support to bring their novel lifesaving device for the everyday use of ... medical-grade sensors, specially designed to read a child’s vital signs, and detect unusual ...
Breaking Medicine News(10 mins):